Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad027 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Karol Mateusz Pencina und 21 weiteren Autor:innen. Beteiligte Einrichtung: Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Ha…. Hauptthemen laut MEDLINE: Overweight, Insulin Resistance. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIDDK NIH HHS, Metro International Biotech.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Context
Nicotinamide adenine dinucleotide (NAD) levels decline with aging and age-related decline in NAD has been postulated to contribute to age-related diseases.
Objective
We evaluated the safety and physiologic effects of NAD augmentation by administering its precursor, β-nicotinamide mononucleotide (MIB-626, Metro International Biotech, Worcester, MA), in adults at risk for age-related conditions.
Methods
Thirty overweight or obese adults, ≥ 45 years, were randomized in a 2:1 ratio to 2 MIB-626 tablets each containing 500 mg of microcrystalline β-nicotinamide mononucleotide or placebo twice daily for 28 days. Study outcomes included safety; NAD and its metabolome; body weight; liver, muscle, and intra-abdominal fat; insulin sensitivity; blood pressure; lipids; physical performance, and muscle bioenergetics.
Results
Adverse events were similar between groups. MIB-626 treatment substantially increased circulating concentrations of NAD and its metabolites. Body weight (difference −1.9 [−3.3, −0.5] kg, P = .008); diastolic blood pressure (difference −7.01 [−13.44, −0.59] mmHg, P = .034); total cholesterol (difference −26.89 [−44.34, −9.44] mg/dL, P = .004), low-density lipoprotein (LDL) cholesterol (−18.73 [−31.85, −5.60] mg/dL, P = .007), and nonhigh-density lipoprotein cholesterol decreased significantly more in the MIB-626 group than placebo. Changes in muscle strength, muscle fatigability, aerobic capacity, and stair-climbing power did not differ significantly between groups. Insulin sensitivity and hepatic and intra-abdominal fat did not change in either group.
Conclusions
MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
- Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA.
- Dana Faber Cancer Center, Boston, MA 02115, USA.
- Metro International Biotech, Worcester, MA 01606, USA.
- Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA.
ORCID-Profile: Shalender Bhasin
Förderung
- NIA NIH HHS
- NIDDK NIH HHS
- Metro International Biotech
- Boston Claude D. Pepper older Americans Independence Center
- NIH
Zitieren
APA
Pencina, K. M., Valderrabano, R., Wipper, B., Orkaby, A. R., Reid, K. F., Storer, T., Lin, A. P., Merugumala, S., Wilson, L., Latham, N., Ghattas-Puylara, C., Ozimek, N. E., Cheng, M., Bhargava, A., Memish-Beleva, Y., Lawney, B., Lavu, S., Swain, P. M., Apte, R. S., …, & Bhasin, S. (2023). Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad027
Vancouver
Pencina KM, Valderrabano R, Wipper B, Orkaby AR, Reid KF, Storer T, et al. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad027
BibTeX
@article{Pencina2023,
author = {Pencina, Karol Mateusz and Valderrabano, Rodrigo and Wipper, Benjamin and Orkaby, Ariela R and Reid, Kieran F and Storer, Thomas and Lin, Alexander P and Merugumala, Sai and Wilson, Lauren and Latham, Nancy and Ghattas-Puylara, Catherine and Ozimek, Noelle E and Cheng, Ming and Bhargava, Avantika and Memish-Beleva, Yusnie and Lawney, Brian and Lavu, Siva and Swain, Pamela M and Apte, Rajendra S and Sinclair, David A and Livingston, David and Bhasin, Shalender},
title = {Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad027}
}
EUVIMED